Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma

Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. However, the overall response rate to immune checkpoint inhibitor therapy for many cancers is only between 20 and 40%, and even less for colorectal cancer (CRC) patients. Thus, there is an urgent need to develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yuyin, Peng, Yujia, Zhao, Shengyan, Mou, Jun, Zeng, Lishi, Jiang, Xiaohua, Yang, Chengli, Huang, Cheng, Li, Yuyan, Lu, Yin, Wu, Mengdan, Yang, Yanfang, Kong, Ting, Lai, Qinhuai, Wu, Yangping, Yao, Yuqin, Wang, Yuxi, Gou, Lantu, Yang, Jinliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298272/
https://www.ncbi.nlm.nih.gov/pubmed/34307367
http://dx.doi.org/10.3389/fcell.2021.689727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298272/
https://www.ncbi.nlm.nih.gov/pubmed/34307367
http://dx.doi.org/10.3389/fcell.2021.689727

Ejemplares similares